Insiders · SCNI

Mark Germain

Director at Scinai Immunotherapeutics Ltd. (SCNI) since January 2023

Mark Germain has filed 2 insider reports with the SEC since January 2023, as director at Scinai Immunotherapeutics Ltd. (SCNI). The latest filing, on June 18, 2026, reports grant or award at Scinai Immunotherapeutics Ltd. (SCNI).

Filings
2
Companies
1
Bought on market
None
Sold on market
None

Companies where Mark Germain is an insider

CompanyRoleShares heldBoughtSoldAvg buyPrice nowLast filing
Scinai Immunotherapeutics Ltd. logo
SCNI
Scinai Immunotherapeutics Ltd.
Directorsince January 2023120,000,000$0.3725Jun 18, 2026

Shares held: common shares owned directly after the latest filing that states it. Avg buy: open-market purchase dollars divided by shares bought, every filing on record.

Every filing

Compare Mark Germain with

Other insiders at the same companies

Questions about Mark Germain

What is Mark Germain's role at Scinai Immunotherapeutics Ltd.?
Mark Germain reports to the SEC as director at Scinai Immunotherapeutics Ltd. (SCNI), according to the latest filing on June 18, 2026.
How many shares does Mark Germain own?
After the latest filing that states it, Mark Germain directly owned 120,000,000 shares of Scinai Immunotherapeutics Ltd. (SCNI). Shares held through trusts, funds or family members are reported separately and are not counted here.
Has Mark Germain bought or sold stock recently?
No open-market purchases or sales by Mark Germain are on file. The filings report grant or award.
How do I get alerts when Mark Germain files?
Follow Mark Germain on Quantisnow and you get an email, and a phone notification on Plus, within minutes of each new Form 4 or Form 5, and of each Form 144 notice of a planned sale.

From SEC Forms 3, 4, 5 and 144 filed by Mark Germain (SEC CIK 0001195498). Totals count each trade once, skipping amendments whose original is on file, from Jan 3, 2023 on. View on SEC EDGAR